PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
 
Br J Cancer. 1987 January; 55(1): 61–66.
PMCID: PMC2001575

The clinical course of bone metastases from breast cancer.

Abstract

All patients with carcinoma of the breast seen in this Unit since 1970 were reviewed to study the incidence, prognosis, morbidity and response to treatment of bone metastases. The biological characteristics of the primary tumour were compared in patients relapsing first in bone or liver. Sixty-nine percent of patients dying with breast cancer had bone metastases and bone was the commonest site of first distant relapse. Bone relapse was more common in receptor positive or well differentiated (grade 1) tumours. The median survival was 24 months in those with disease apparently confined to the skeleton compared with 3 months after first relapse in liver. Ten percent of patients with breast cancer developed hypercalcaemia. All had metastatic disease and 85% had widespread skeletal involvement. Fifteen percent of patients with disease confined to the skeleton developed hypercalcaemia. The response in bone to primary endocrine therapy, and chemotherapy, was apparently less than the overall response achieved. A large proportion had apparently static disease reflecting the insensitivity of the UICC assessment criteria. The duration of survival in these patients was similar to responding patients, suggesting a tumour response may occur in the absence of discernable radiological evidence of healing.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (879K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • BLOOM HJ, RICHARDSON WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957 Sep;11(3):359–377. [PMC free article] [PubMed]
  • Coleman RE, Rubens RD. Bone metastases and breast cancer. Cancer Treat Rev. 1985 Dec;12(4):251–270. [PubMed]
  • Croton R, Cooke T, Holt S, George WD, Nicolson R, Griffiths K. Oestrogen receptors and survival in early breast cancer. Br Med J (Clin Res Ed) 1981 Nov 14;283(6302):1289–1291. [PMC free article] [PubMed]
  • Lee YT. Patterns of metastasis and natural courses of breast carcinoma. Cancer Metastasis Rev. 1985;4(2):153–172. [PubMed]
  • McNeil BJ. Value of bone scanning in neoplastic disease. Semin Nucl Med. 1984 Oct;14(4):277–286. [PubMed]
  • Stewart J, King R, Hayward J, Rubens R. Estrogen and progesterone receptors: correlation of response rates, site and timing of receptor analysis. Breast Cancer Res Treat. 1982;2(3):243–250. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK